Arcus Biosciences Overview
- Founded
-
2015
- Status
-
Public
- Employees
-
500
- Stock Symbol
-
RCUS
- Share Price
-
$16.36
- (As of Thursday Closing)
Arcus Biosciences General Information
Description
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB680, and Zimberelimab. Arcus conducts clinical trials for different types of cancers such as Prostate, Lung, Colorectal, Pancreatic, and others. The company operates through the single segment being the business of developing and commercializing immunotherapies.
Contact Information
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NYS
Primary Office
- 3928 Point Eden Way
- Hayward, CA 94545
- United States
+1 (510) 000-0000
Arcus Biosciences Timeline
Arcus Biosciences Stock Performance
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $16.36 | $15.96 | $15.70 - $39.75 | $1.17B | 73M | 1.12M | -$3.71 |
Arcus Biosciences Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 567,804 | 567,804 | 2,367,297 | 902,977 |
| Revenue | 112,000 | 112,000 | 383,000 | 78,000 |
| EBITDA | (274,000) | (274,000) | 58,000 | (121,000) |
| Net Income | (267,000) | (267,000) | 53,000 | (123,000) |
| Total Assets | 1,345,000 | 1,345,000 | 1,592,000 | 772,292 |
| Total Debt | 0 | 0 | 0 | 15,243 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Arcus Biosciences Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Arcus Biosciences Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Arcus Biosciences Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of ca
Biotechnology
Hayward, CA
500
As of 2022
00000
0.000
0000-00-00
000000000
00000
000000
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor i
0000000000000
Hampton, NJ
000
As of 0000
00000
00000000
00000
000000
is nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
0000000000000
South San Francisco, CA
000
As of 0000
00000
0.000
0000-00-00
00000000
00000
Add Comparison
Arcus Biosciences Competitors (65)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Celldex Therapeutics | Formerly VC-backed | Hampton, NJ | 000 | 00000 | 00000000 | 00000 |
| 00000000 000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
| 000000 00000000000 | Corporation | Cambridge, MA | 000 | 00000 | 000000&0 | 00000 |
| 000000 00000000000 | Formerly VC-backed | South San Francisco, CA | 000 | 00000 | 00000000 | 00000 |
| 00000000 | Formerly VC-backed | San Carlos, CA | 00 | 00000 | 000000000 | 00000 |
Arcus Biosciences Patents
Arcus Biosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2021292195-A1 | Crystalline forms of a cd73 inhibitor and uses thereof | Pending | 17-Jun-2020 | 000000000 | |
| CA-3179320-A1 | Crystalline forms of a cd73 inhibitor and uses thereof | Pending | 17-Jun-2020 | 000000000 | |
| US-20210395291-A1 | Crystalline forms of a cd73 inhibitor and uses thereof | Pending | 17-Jun-2020 | 000000000 | 0 |
| AU-2021284273-A1 | Antibodies to tigit | Pending | 02-Jun-2020 | 00000000000 | |
| CA-3176246-A1 | Antibodies to tigit | Pending | 02-Jun-2020 | C07K16/2809 |
Arcus Biosciences Executive Team (21)
Arcus Biosciences Board Members (15)
| Name | Representing | Role | Since |
|---|---|---|---|
| Andrew Perlman Ph.D | Arcus Biosciences | Board Member | 000 0000 |
| Antoni Ribas Ph.D | Self | Board Member | 000 0000 |
| David Lacey MD | Arcus Biosciences | Board Member | 000 0000 |
| Jennifer Jarrett | Arcus Biosciences | Chief Operating Officer, Operations & Board Member | 000 0000 |
| Juan Jaen Ph.D | Arcus Biosciences | Founder, President & Board Member | 000 0000 |
Arcus Biosciences Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Arcus Biosciences Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Arcus Biosciences ESG
Risk Overview
Risk Rating
Updated December, 02, 2022
31.33 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,231
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 899
Rank
00.00
Percentile
Biotechnology
Subindustry
00 of 401
Rank
00.00
Percentile
